Stock OMGA OMEGA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Real-time Estimate Cboe BZX
Other stock markets
 11:05:34 13/05/2024 pm IST 		5-day change 1st Jan Change
2.325 USD +18.62% Intraday chart for Omega Therapeutics, Inc. +2.63% -22.26%
06/05 Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
16/04 Omega Therapeutics CFO Joshua Reed to Depart MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
GL
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
GL
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
GL
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
GL
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
GL
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
GL
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
GL
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
AQ
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
GL
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
GL
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
GL
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
GL
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
AQ
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
GL
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
AQ
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
GL
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OMGA Stock
  4. News Omega Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW